ASCO 2026 Special — Comprehensive Opening Weekend: Daraxonrasib Doubles Pancreatic OS

ASCO 2026 comprehensive opening-weekend recap (28 readouts through Sunday, May 31). Headline: Revolution Medicines' RASolute 302 doubles overall survival in second-line pancreatic cancer (daraxonrasib, 13.2 vs 6.7months, HR 0.40). LUNG: CROWN 7-year (lorlatinib 55% vs 3% PFS), LIBRETTO-432 adjuvant selpercatinib (83% reduction), WU-KONG28 sunvozertinib, HARMONi-6ivonescimab (34% OS, soft reaction), OptiTROP-Lung05 sac-TMT (PFS HR 0.35), plus ROSETTA Lung-02, CHRYSALIS-2, Krascendo-170, elisrasib. BREAST: KEYNOTE-522 7-yr OS (85.1% vs 77.2%), lidERA. GI: RASolute 302, CIRCULATE ctDNA-guidedcolon, EPISODE-III aspirin miss. PROSTATE: PROTEUS, TALAPRO-3 (PARP into mHSPC rPFS HR 0.481). KIDNEY: RAMPART split. HEAD & NECK: TMC-I (~$225/moregimen, 43% death-risk reduction). GLIOMA: INDIGO vorasidenib (PFS 44.1mo). SARCOMA: SARC041 abemaciclib. HEME: MajesTEC-9 teclistamab, SUCCESSOR-2 mezigdomide, frontMIND tafasitamab, golcadomide, PRIMAVERA. MELANOMA: IGNYTE/RP1. SCREENING: NHS-Galleri miss. Plus the June 1-2 forward look.pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ASCO 2026,Revolution Medicines, daraxonrasib, RASolute 302, RAS, KRAS, pancreatic cancer,lorlatinib, CROWN, Pfizer, selpercatinib, LIBRETTO-432, RET fusion, lungcancer, NSCLC, sunvozertinib, WU-KONG28, Dizal, ivonescimab, HARMONi-6, Akeso,Summit Therapeutics, bispecific, sacituzumab tirumotecan, OptiTROP-Lung05,Kelun, Merck, ADC, pumitamig, BioNTech, amivantamab, lazertinib, CHRYSALIS-2,divarasib, Krascendo-170, elisrasib, pembrolizumab, KEYNOTE-522,triple-negative breast cancer, giredestrant, lidERA, Roche, CIRCULATE, ctDNA,colorectal cancer, EPISODE-III, aspirin, PROTEUS, apalutamide, Erleada,prostate cancer, Johnson & Johnson, talazoparib, enzalutamide, TALAPRO-3,PARP, RAMPART, durvalumab, kidney cancer, AstraZeneca, TMC-I, nivolumab, headand neck cancer, Tata Memorial, vorasidenib, INDIGO, glioma, Servier, SARC041,abemaciclib, liposarcoma, sarcoma, teclistamab, MajesTEC-9, mezigdomide,SUCCESSOR-2, multiple myeloma, BMS, tafasitamab, frontMIND, Incyte, DLBCL,golcadomide, PRIMAVERA, AZD3470, Hodgkin lymphoma, RP1, IGNYTE, Replimune,melanoma, NHS-Galleri, GRAIL, MCED, early detection, MARIPOSA, oncology, Lilly,J&J